REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after...
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...
Coherus BioSciences is selling its Humira biosimilar for just $40 million, only three years after it won FDA approval, showing just how crowded the market
Eight months after becoming the first China-made PD-1 inhibitor to score an approval in the United States, Junshi and Coherus’ Loqtorzi (toripalimab) appears set up to win clearance in a second indication.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice...
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the 2024 Jefferies Global Healthcare...
REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual...
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T...
“ New $38.7 million term loan with a May 2029 maturity ““ $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® “ REDWOOD CITY, Calif., May 09, 2024 (GLOBE...
“ Net revenue of $77.1 million in Q1 2024 “ “ CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer “ “ New debt and royalty financing replaces $75 million...